Siemens Healthineers Licenses Technology from Kromek for CZT-based SPECT Detector Production

Siemens Healthineers has entered into a technology licensing agreement with Kromek Group Plc, a UK-based developer of radiation detection solutions, to enable the in-house production of cadmium zinc telluride (CZT) material for gamma ray detectors used in single-photon emission computed tomography (SPECT) systems. Under the terms of the agreement, Siemens Healthineers will license Kromek’s technology to produce CZT, which will extend its research, development, and manufacturing capabilities to allow for a potential future line of gamma ray detectors for multi-modal SPECT systems.

“Bringing this production technology in-house is a key step to optimizing the process and material for our own applications,” said Jim Williams, head of the Molecular Imaging business at Siemens Healthineers.

Expansion of Siemens Healthineers CZT research efforts will run in parallel with continued development of its sodium iodide (Nal) SPECT innovations. The sodium iodide-based SPECT systems will continue to be in high demand due to their versatility and ability to perform all nuclear medicine applications, including theranostics.

CZT can detect radiation without requiring the conversion of gamma radiation to optical light at room temperature. It offers high-energy resolution measurement, which can be a key factor in enabling certain detector and system designs. 

“We are vertically integrated in all our molecular imaging detector material technologies for both positron emission tomography (PET) and SPECT,” said Williams. “This vertical integration allows us to precisely tune performance and optimize cost for our clinical systems.”

Jeff Bell
Phone: (484) 868-8346
Phone: jeffrey.t.bell@siemens-healthineers.com

Visit the  Siemens Healthineers Press Center

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.